Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Urologix' Building Momentum, New COO Help Boost Stock 63% In November

This article was originally published in The Gray Sheet

Executive Summary

Continued momentum in sales of Urologix' Targis microwave catheter-based system for treatment of benign prostatic hyperplasia and procedure kit revenues, as well as growing acceptance of a "per-procedure" marketing strategy and strong additions to top management, helped Urologix stock jump 62.7% in November. The issue gained 2 points to close at 5-3/16

You may also be interested in...



Kimberly-Clark Enters $3 Bil. Glove Market Via $850 Mil. Safeskin Buy

Acquisition of disposable medical glove maker Safeskin marks Kimberly-Clark's entrance into the $3 bil. worldwide latex and synthetic glove market and will boost sales of the firm's professional health care segment to approximately $950 mil. in 2000.

Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel